Table of Contents

March 1, 2005; 142 (5)

Articles

  • Incidence of Type 2 Diabetes in the Randomized Multiple Risk Factor Intervention Trial

    • George Davey Smith,
    • Yiscah Bracha,
    • Kenneth H. Svendsen,
    • James D. Neaton,
    • Steven M. Haffner,
    • Lewis H. Kuller,
    • and for the Multiple Risk Factor Intervention Trial Research Group*
    Ann Intern Med March 1, 2005 142:313-322

    In previous trials of strategies to prevent type 2 diabetes, the participants had impaired glucose tolerance. This secondary analysis of the Multiple Risk Factor Intervention Trial (MRFIT) studied people with normal glucose tolerance. In nonsmokers, interventions to change diet and increase exercise reduced the risk for diabetes.

  • The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance

    • William H. Herman,
    • Thomas J. Hoerger,
    • Michael Brandle,
    • Katherine Hicks,
    • Stephen Sorensen,
    • Ping Zhang,
    • Richard F. Hamman,
    • Ronald T. Ackermann,
    • Michael M. Engelgau,
    • Robert E. Ratner,
    • and for the Diabetes Prevention Program Research Group*
    Ann Intern Med March 1, 2005 142:323-332

    This cost-effectiveness analysis estimates that the Diabetes Prevention Program's lifestyle intervention would cost society about $8800 per quality-adjusted life-year saved. The corresponding result for metformin was $29 900. The lifestyle intervention was cost-effective at any adult age; metformin was not cost-effective after age 65 years.

  • Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up

    • Brian J. McMahon,
    • Dana L. Bruden,
    • Kenneth M. Petersen,
    • Lisa R. Bulkow,
    • Alan J. Parkinson,
    • Omana Nainan,
    • Marina Khristova,
    • Carolyn Zanis,
    • Helen Peters,
    • and Harold S. Margolis
    Ann Intern Med March 1, 2005 142:333-341

    The duration of protection afforded by hepatitis B vaccination is unknown. In this cohort of Alaska Natives who received vaccination against hepatitis, antibody levels decreased over a 15-year period, but breakthrough hepatitis B virus infection was very infrequent in all age groups.

  • The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study

    • Mark J. Sarnak,
    • Tom Greene,
    • Xuelei Wang,
    • Gerald Beck,
    • John W. Kusek,
    • Allan J. Collins,
    • and Andrew S. Levey
    Ann Intern Med March 1, 2005 142:342-351

    The optimal blood pressure to slow progression of chronic kidney disease is not known. In this report of long-term follow-up of patients with a moderately to severely decreased glomerular filtration rate in the Modification of Diet in Renal Disease Study, random assignment to a low target blood pressure slowed the progression of nondiabetic kidney disease.

Improving Patient Care

  • Fumbled Handoffs: One Dropped Ball after Another

    • Tejal K. Gandhi
    Ann Intern Med March 1, 2005 142:352-358

    This article, part of the Quality Grand Rounds series, examines the case of a patient whose diagnosis of tuberculosis was substantially delayed because of systems problems, including poor continuity of care, failure to communicate test results and other clinical information, and several mismanaged handoffs. The article discusses strategies to ensure adequate communication of critical information and follow-up of test results.

Reviews

  • Meta-Analysis: Test Performance of Ultrasonography for Giant-Cell Arteritis

    • Fotini B. Karassa,
    • Miltiadis I. Matsagas,
    • Wolfgang A. Schmidt,
    • and John P.A. Ioannidis
    Ann Intern Med March 1, 2005 142:359-369

    This meta-analysis shows a sensitivity and specificity of 86% when the halo sign or occlusion or stenosis is present. The post-test probability is low if none of these findings are present and the pretest probability is low. Ultrasonography can be useful for giant-cell arteritis if interpreted in light of the patient's clinical presentation.

  • Narrative Review: Aspirin Resistance and Its Clinical Implications

    • Simon Sanderson,
    • Jon Emery,
    • Trevor Baglin,
    • and Ann-Louise Kinmonth
    Ann Intern Med March 1, 2005 142:370-380

    Aspirin is an important drug for the secondary prevention of cardiovascular disease, but recurrent vascular events are common even when patients take aspirin. This paper reviews the concept of aspirin resistance, its measurement, and its clinical consequences for patients prescribed aspirin to prevent recurrences of cardiovascular disease.

Editorials

  • Primary Prevention of Type 2 Diabetes: Lifestyle Intervention Works and Saves Money, but What Should Be Done with Smokers?

    • Jaakko Tuomilehto
    Ann Intern Med March 1, 2005 142:381-383

    Many large public health problems and epidemics have been overcome by acting on much less evidence than we have for preventing type 2 diabetes. Therefore, we should act as if vigorous measures could control the emerging epidemic of diabetes, even though we may not eradicate this disease in those with a strong genetic background.

  • Long-Term Protection of Hepatitis B Vaccine: Lessons from Alaskan Experience after 15 Years

    • Ding-Shinn Chen
    Ann Intern Med March 1, 2005 142:384-385

    McMahon and colleagues' study in this issue reveals that serum levels of antibodies to hepatitis B surface antigen declined faster in persons who were immunized at 0.5 to 4 years of age. However, unless continued surveillance shows clinically significant rates of infection in adolescents or adults who were vaccinated as children, booster vaccinations will be wasteful.

Letters

  • Care Management for Heart Failure

    • Ariel Linden and
    • Thomas Wilson
    Ann Intern Med March 1, 2005 142:386

  • Care Management for Heart Failure

    • Robert F. DeBusk,
    • Daniel J. Cher,
    • and Helena C. Kraemer
    Ann Intern Med March 1, 2005 142:386

  • Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure

    • Mark B. McClellan,
    • Jerod M. Loeb,
    • Carolyn M. Clancy,
    • Gary S. Francis,
    • Alice K. Jacobs,
    • Kenneth W. Kizer,
    • Margaret E. O'Kane,
    • and Michael J. Wolk
    Ann Intern Med March 1, 2005 142:386-387

  • Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure

    • Michael J. Peeters and
    • James P. Tsikouris
    Ann Intern Med March 1, 2005 142:388

  • Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure

    • Loren D. Regier and
    • Brent Jensen
    Ann Intern Med March 1, 2005 142:388

  • Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure

    • Victor C. Lee,
    • David C. Rhew,
    • and Glenn D. Braunstein
    Ann Intern Med March 1, 2005 142:388-389

  • Demarcated Truncal Jaundice: A Sign of Retroperitoneal Bile Leakage

    • Vivian C. McAlister and
    • Alp Sener
    Ann Intern Med March 1, 2005 142:389

  • The International Campaign to Revitalise Academic Medicine

    • Crispin Hiley and
    • Andrew Robertson
    Ann Intern Med March 1, 2005 142:390-391

  • Correction: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction

    Ann Intern Med March 1, 2005 142:391

Medical Writings: Book Notes

  • Travel Medicine

    • Pierce Gardner
    Ann Intern Med March 1, 2005 142:392

  • Taking Advance Directives Seriously: Prospective Autonomy and Decisions Near the End of Life

    • Mark D. Hannis
    Ann Intern Med March 1, 2005 142:392

Medical Notices

  • Medical Notices

    Ann Intern Med March 1, 2005 142:0

Summaries for Patients

  • Development of Type 2 Diabetes among People Participating in a Program To Promote Healthy Behaviors

    Ann Intern Med March 1, 2005 142:I-17

  • The Cost-Effectiveness of Strategies To Prevent Type 2 Diabetes

    Ann Intern Med March 1, 2005 142:I-28

  • Does Hepatitis B Vaccination Protection Continue after 15 Years?

    Ann Intern Med March 1, 2005 142:I-34

  • A Low Blood Pressure Target Prevented Kidney Failure in Patients with Chronic Kidney Disease

    Ann Intern Med March 1, 2005 142:I-42

  • Ultrasonography To Diagnose Giant-Cell Arteritis

    Ann Intern Med March 1, 2005 142:I-44
« Previous | Next Issue »

This Issue

March 1, 2005; 142 (5)
  1. Articles
  2. Improving Patient Care
  3. Reviews
  4. Editorials
  5. Letters
  6. Medical Writings: Book Notes
  7. Medical Notices
  8. Summaries for Patients

Search in this issue:

Current Issue

  1. November 3, 2009, 151 (9)
  1. Alert me to current issues